PYXS is trading at $2.85 (-5.15%) after announcing a $114 million private placement financing priced at $2.551 per share, representing a discount to its prior close.
- The deal is expected to close around July 2, with shares facing pressure as investors digest the associated dilution risk.
- The company expects the financing to extend its cash runway into Q2 2027 and fund the development of MICVO through key clinical milestones.
- The downward move appears to be company-specific rather than driven by broader market trends.